BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 16998806)

  • 1. Absence of Bcl-2 expression favors response to the short-term administration of diethylstilbestrol diphosphate in prostate Cancer.
    Nagaoka A; Kubota Y; Kurosu S; Nakada T; Bilim V; Tomita Y; Motoyama T
    Prostate; 2006 Dec; 66(16):1779-87. PubMed ID: 16998806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
    Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
    J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
    Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment.
    Miyata Y; Kanda S; Sakai H; Hakariya T; Kanetake H
    Urology; 2005 Jun; 65(6):1238-43. PubMed ID: 15922418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer.
    Francini G; Paolelli L; Francini E; Pascucci A; Manganelli A; Salvestrini F; Petrioli R
    Eur J Surg Oncol; 2008 Feb; 34(2):216-21. PubMed ID: 17502132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
    Imasato Y; Xuan JW; Sakai H; Izawa JI; Saito Y; Chin JL; Moussa M
    J Urol; 2000 Nov; 164(5):1819-24. PubMed ID: 11025776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence.
    Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H
    Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review.
    Qiu YQ; Leuschner I; Braun PM
    Asian J Androl; 2008 Nov; 10(6):855-63. PubMed ID: 18958349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis in prostate cancer: bax correlation with stage.
    Amirghofran Z; Monabati A; Gholijani N
    Int J Urol; 2005 Apr; 12(4):340-5. PubMed ID: 15948719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population.
    Inoue T; Segawa T; Shiraishi T; Yoshida T; Toda Y; Yamada T; Kinukawa N; Kinoshita H; Kamoto T; Ogawa O
    Urology; 2005 Aug; 66(2):332-7. PubMed ID: 16098362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
    Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
    Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathological significance of neoadjuvant hormonal therapy prior to radical prostatectomy: whole section analysis].
    Uemura H; Cho M; Hirao Y; Konishi N
    Hinyokika Kiyo; 2002 Nov; 48(11):719-23. PubMed ID: 12512148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
    Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
    J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized trial for treating stages B2 and C prostate cancer: radical surgery or irradiation with neoadjuvant endocrine therapy.
    Isaka S; Shimazaki J; Akimoto S; Okada K; Yoshida O; Arai Y; Usami M; Kotake T; Tobisu K; Kakizoe T
    Jpn J Clin Oncol; 1994 Aug; 24(4):218-23. PubMed ID: 8072201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of repeated biopsies in prognosis of prostate cancer].
    Romics I; Lovász S; Szabó J; Szomor L; Minik K; Bartók K; Kerényi T; Szende B
    Orv Hetil; 2002 Jul; 143(27):1619-23. PubMed ID: 12179998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation therapy affects BCL-2 expression in human prostate cancer.
    Fuzio P; Ditonno P; Lucarelli G; Battaglia M; Bettocchi C; Senia T; Perlino E
    Int J Oncol; 2011 Nov; 39(5):1233-42. PubMed ID: 21785821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.
    Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS
    BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity.
    Grossfeld GD; Olumi AF; Connolly JA; Chew K; Gibney J; Bhargava V; Waldman FM; Carroll PR
    J Urol; 1998 May; 159(5):1437-43. PubMed ID: 9554329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
    Goto T; Nguyen BP; Nakano M; Ehara H; Yamamoto N; Deguchi T
    Urology; 2008 Jul; 72(1):167-71. PubMed ID: 18384856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.